Are you involved in a clinical trial funded by the National Cancer Institute (NCI)? If so, you can take advantage of NanoString’s collaboration with the NCI to gain special access to our PanCancer IO 360TM Gene Expression Panel and data analysis service.
This collaboration supports NCI efforts to implement novel strategies to correlate therapeutic treatment with patient response across a range of tumor types by incorporating the PanCancer IO 360 panel into select active and future NCI-sponsored clinical trials.
This 770 gene panel for Research Use Only (RUO) allows you to characterize mechanisms of tumor immune evasion and identify targetable therapeutic pathways by leveraging several gene signatures that describe key biological processes such as the 18 gene Tumor Inflammation Signature (learn more about the Biological Signatures in the PanCancer IO 360 Gene Expression Panel). You can also add up to 30 genes of interest as a Panel Plus customization to fully tailor the biological content of the panel to meet your needs.